The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Checkpoint Inhibitors for Treating Cancer-Global Market Insights and Sales Trends 2025
Synopsis
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
The global Checkpoint Inhibitors for Treating Cancer market size is expected to reach US$ 62650 million by 2029, growing at a CAGR of 25.6% from 2023 to 2029. The market is mainly driven by the significant applications of Checkpoint Inhibitors for Treating Cancer in various end use industries. The expanding demands from the Melanoma Treatment, Bladder Cancer Treatment and Other, are propelling Checkpoint Inhibitors for Treating Cancer market. PD-1 Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the PD-L1 Inhibitors segment is estimated at % CAGR for the next seven-year period.
The major players in global Checkpoint Inhibitors for Treating Cancer market include Bristol-Myers Squibb(BMS), Merck, etc., and the market concentration rate is high. North America is the main market, and occupies about 95% of the global market. PD-1 Inhibitors is the main type, with a share about 80%. Melanoma Treatment is the main application, which holds a share about 80%.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Checkpoint Inhibitors for Treating Cancer, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Checkpoint Inhibitors for Treating Cancer market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Checkpoint Inhibitors for Treating Cancer market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Checkpoint Inhibitors for Treating Cancer sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Checkpoint Inhibitors for Treating Cancer covered in this report include Bristol-Myers Squibb(BMS), Merck and Roche, etc.
The global Checkpoint Inhibitors for Treating Cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bristol-Myers Squibb(BMS)
Merck
Roche
Global Checkpoint Inhibitors for Treating Cancer market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Checkpoint Inhibitors for Treating Cancer market, Segment by Type:
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Global Checkpoint Inhibitors for Treating Cancer market, by Application
Melanoma Treatment
Bladder Cancer Treatment
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Checkpoint Inhibitors for Treating Cancer manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Checkpoint Inhibitors for Treating Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
The global Checkpoint Inhibitors for Treating Cancer market size is expected to reach US$ 62650 million by 2029, growing at a CAGR of 25.6% from 2023 to 2029. The market is mainly driven by the significant applications of Checkpoint Inhibitors for Treating Cancer in various end use industries. The expanding demands from the Melanoma Treatment, Bladder Cancer Treatment and Other, are propelling Checkpoint Inhibitors for Treating Cancer market. PD-1 Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the PD-L1 Inhibitors segment is estimated at % CAGR for the next seven-year period.
The major players in global Checkpoint Inhibitors for Treating Cancer market include Bristol-Myers Squibb(BMS), Merck, etc., and the market concentration rate is high. North America is the main market, and occupies about 95% of the global market. PD-1 Inhibitors is the main type, with a share about 80%. Melanoma Treatment is the main application, which holds a share about 80%.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Checkpoint Inhibitors for Treating Cancer, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Checkpoint Inhibitors for Treating Cancer market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Checkpoint Inhibitors for Treating Cancer market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Checkpoint Inhibitors for Treating Cancer sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Checkpoint Inhibitors for Treating Cancer covered in this report include Bristol-Myers Squibb(BMS), Merck and Roche, etc.
The global Checkpoint Inhibitors for Treating Cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bristol-Myers Squibb(BMS)
Merck
Roche
Global Checkpoint Inhibitors for Treating Cancer market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Checkpoint Inhibitors for Treating Cancer market, Segment by Type:
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Global Checkpoint Inhibitors for Treating Cancer market, by Application
Melanoma Treatment
Bladder Cancer Treatment
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Checkpoint Inhibitors for Treating Cancer manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Checkpoint Inhibitors for Treating Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Checkpoint Inhibitors for Treating Cancer Market Overview
1.1 Checkpoint Inhibitors for Treating Cancer Product Overview
1.2 Checkpoint Inhibitors for Treating Cancer Market Segment by Type
1.2.1 PD-1 Inhibitors
1.2.2 PD-L1 Inhibitors
1.2.3 CTLA-4 Inhibitors
1.3 Global Checkpoint Inhibitors for Treating Cancer Market Size by Type
1.3.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Overview by Type (2018-2029)
1.3.2 Global Checkpoint Inhibitors for Treating Cancer Historic Market Size Review by Type (2018-2023)
1.3.3 Global Checkpoint Inhibitors for Treating Cancer Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Type (2018-2023)
1.4.2 Europe Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Type (2018-2023)
2 Global Checkpoint Inhibitors for Treating Cancer Market Competition by Company
2.1 Global Top Players by Checkpoint Inhibitors for Treating Cancer Sales (2018-2023)
2.2 Global Top Players by Checkpoint Inhibitors for Treating Cancer Revenue (2018-2023)
2.3 Global Top Players by Checkpoint Inhibitors for Treating Cancer Price (2018-2023)
2.4 Global Top Manufacturers Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution, Sales Area, Product Type
2.5 Checkpoint Inhibitors for Treating Cancer Market Competitive Situation and Trends
2.5.1 Checkpoint Inhibitors for Treating Cancer Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Checkpoint Inhibitors for Treating Cancer Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Checkpoint Inhibitors for Treating Cancer as of 2022)
2.7 Date of Key Manufacturers Enter into Checkpoint Inhibitors for Treating Cancer Market
2.8 Key Manufacturers Checkpoint Inhibitors for Treating Cancer Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Checkpoint Inhibitors for Treating Cancer Status and Outlook by Region
3.1 Global Checkpoint Inhibitors for Treating Cancer Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Checkpoint Inhibitors for Treating Cancer Historic Market Size by Region
3.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales in Volume by Region (2018-2023)
3.2.2 Global Checkpoint Inhibitors for Treating Cancer Sales in Value by Region (2018-2023)
3.2.3 Global Checkpoint Inhibitors for Treating Cancer Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Checkpoint Inhibitors for Treating Cancer Forecasted Market Size by Region
3.3.1 Global Checkpoint Inhibitors for Treating Cancer Sales in Volume by Region (2024-2029)
3.3.2 Global Checkpoint Inhibitors for Treating Cancer Sales in Value by Region (2024-2029)
3.3.3 Global Checkpoint Inhibitors for Treating Cancer Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Checkpoint Inhibitors for Treating Cancer by Application
4.1 Checkpoint Inhibitors for Treating Cancer Market Segment by Application
4.1.1 Melanoma Treatment
4.1.2 Bladder Cancer Treatment
4.1.3 Other
4.2 Global Checkpoint Inhibitors for Treating Cancer Market Size by Application
4.2.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Overview by Application (2018-2029)
4.2.2 Global Checkpoint Inhibitors for Treating Cancer Historic Market Size Review by Application (2018-2023)
4.2.3 Global Checkpoint Inhibitors for Treating Cancer Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Application (2018-2023)
4.3.2 Europe Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Breakdown by Application (2018-2023)
5 North America Checkpoint Inhibitors for Treating Cancer by Country
5.1 North America Checkpoint Inhibitors for Treating Cancer Historic Market Size by Country
5.1.1 North America Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Checkpoint Inhibitors for Treating Cancer Sales in Volume by Country (2018-2023)
5.1.3 North America Checkpoint Inhibitors for Treating Cancer Sales in Value by Country (2018-2023)
5.2 North America Checkpoint Inhibitors for Treating Cancer Forecasted Market Size by Country
5.2.1 North America Checkpoint Inhibitors for Treating Cancer Sales in Volume by Country (2024-2029)
5.2.2 North America Checkpoint Inhibitors for Treating Cancer Sales in Value by Country (2024-2029)
6 Europe Checkpoint Inhibitors for Treating Cancer by Country
6.1 Europe Checkpoint Inhibitors for Treating Cancer Historic Market Size by Country
6.1.1 Europe Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Checkpoint Inhibitors for Treating Cancer Sales in Volume by Country (2018-2023)
6.1.3 Europe Checkpoint Inhibitors for Treating Cancer Sales in Value by Country (2018-2023)
6.2 Europe Checkpoint Inhibitors for Treating Cancer Forecasted Market Size by Country
6.2.1 Europe Checkpoint Inhibitors for Treating Cancer Sales in Volume by Country (2024-2029)
6.2.2 Europe Checkpoint Inhibitors for Treating Cancer Sales in Value by Country (2024-2029)
7 Asia-Pacific Checkpoint Inhibitors for Treating Cancer by Region
7.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Historic Market Size by Region
7.1.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Forecasted Market Size by Region
7.2.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales in Value by Region (2024-2029)
8 Latin America Checkpoint Inhibitors for Treating Cancer by Country
8.1 Latin America Checkpoint Inhibitors for Treating Cancer Historic Market Size by Country
8.1.1 Latin America Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Checkpoint Inhibitors for Treating Cancer Sales in Volume by Country (2018-2023)
8.1.3 Latin America Checkpoint Inhibitors for Treating Cancer Sales in Value by Country (2018-2023)
8.2 Latin America Checkpoint Inhibitors for Treating Cancer Forecasted Market Size by Country
8.2.1 Latin America Checkpoint Inhibitors for Treating Cancer Sales in Volume by Country (2024-2029)
8.2.2 Latin America Checkpoint Inhibitors for Treating Cancer Sales in Value by Country (2024-2029)
9 Middle East and Africa Checkpoint Inhibitors for Treating Cancer by Country
9.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Historic Market Size by Country
9.1.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Forecasted Market Size by Country
9.2.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Bristol-Myers Squibb(BMS)
10.1.1 Bristol-Myers Squibb(BMS) Company Information
10.1.2 Bristol-Myers Squibb(BMS) Introduction and Business Overview
10.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Products Offered
10.1.5 Bristol-Myers Squibb(BMS) Recent Development
10.2 Merck
10.2.1 Merck Company Information
10.2.2 Merck Introduction and Business Overview
10.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Merck Checkpoint Inhibitors for Treating Cancer Products Offered
10.2.5 Merck Recent Development
10.3 Roche
10.3.1 Roche Company Information
10.3.2 Roche Introduction and Business Overview
10.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Roche Checkpoint Inhibitors for Treating Cancer Products Offered
10.3.5 Roche Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Checkpoint Inhibitors for Treating Cancer Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Checkpoint Inhibitors for Treating Cancer Industrial Chain Analysis
11.4 Checkpoint Inhibitors for Treating Cancer Market Dynamics
11.4.1 Checkpoint Inhibitors for Treating Cancer Industry Trends
11.4.2 Checkpoint Inhibitors for Treating Cancer Market Drivers
11.4.3 Checkpoint Inhibitors for Treating Cancer Market Challenges
11.4.4 Checkpoint Inhibitors for Treating Cancer Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Checkpoint Inhibitors for Treating Cancer Distributors
12.3 Checkpoint Inhibitors for Treating Cancer Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
